Hidradenitis Suppurativa Pipeline Landscape: Novel Emerging Therapies and Key Pharmaceutical Companies Reinvigorates the Pipeline Landscape

The Hidradenitis Suppurativa pipeline landscape includes several therapies with different mechanisms of action currently being studied with great market potential. Ongoing scientific research has provided greater sophistication and a clearer understanding of the mechanisms of therapeutic interventions for Hidradenitis suppurativa.

New Delhi, INDIA


Los Angeles, July 14, 2021 (GLOBE NEWSWIRE) -- Hidradenitis Suppurativa Pipeline Landscape: Novel Emerging Therapies and Key Pharmaceutical Companies Reinvigorates the Pipeline Landscape

The Hidradenitis Suppurativa pipeline landscape includes several therapies with different mechanisms of action currently being studied with great market potential. Ongoing scientific research has provided greater sophistication and a clearer understanding of the mechanisms of therapeutic interventions for Hidradenitis suppurativa.

DelveInsight's 'Hidradenitis Suppurativa Pipeline Insights' report presents an exhaustive coverage of the available therapies, Hidradenitis Suppurativa emerging drug therapies in different phases of clinical development, key companies working to advance the Hidradenitis Suppurativa pipeline therapies, and the future market scope of the space. 

Some of the notable pointers extracted from the Hidradenitis Suppurativa (HS) Pipeline report:

  • DelveInsight's analysis depicts a robust Hidradenitis Suppurativa Pipeline with 25+ active players in the domain working on 25+ pipeline therapies. 
  • Key Hidradenitis Suppurativa pipeline therapies such as Bermekimab (MABp1), IFX-1, INCB054707, Secukinumab, Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody, Avacopan, Bimekizumab, and others are under different phases of clinical trials for Hidradenitis Suppurativa. 
  • Janssen, InflaRx, Incyte Corporation, Novartis, CSL Behring, ChemoCentryx, UCB Biopharma S.P.R.L., Eli Lilly and Company, AbbVie, ChemoCentryx, IntegoGen, Pfizer, TO Pharmaceuticals, Kymera Therapeutics, Aclaris Therapeutics, Amgen, Innovation Pharmaceuticals, AnaptysBio, MoonLake Immunotherapeutics, IntegoGen, LLC among several others, are some of the key prominent pharma players working in the domain. 
  • InflaRx's lead drug candidate, vilobelimab (IFX-1), is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical development for several indications including Hidradenitis Suppurativa (HS), a chronic debilitating systemic skin disease. The Company received scientific advice from the European Medicines Agency (EMA) about the European pathway for regulatory approval in July 2020. The Company is working diligently to address the feedback received from the agencies and analyzing the strategy for its Phase III development in HS.
  • Topline data from AURORA Phase II clinical trial of Avacopan in Hidradenitis Suppurativa demonstrated a statistically significant higher response with avacopan at 30 mg BID than placebo in the pre-specified Hurley Stage III (severe) Hidradenitis Suppurativa patients. ChemoCentryx plans to advance Avacopan into Phase III development for the treatment of patients with the most severe form of Hidradenitis Suppurativa.
  • Orismilast, Type 4 cyclic nucleotide phosphodiesterase inhibitors are being developed by Union Therapeutics for psoriasis, atopic dermatitis, and hidradenitis suppurativa. 
  • An Open-label Phase I/II proof of concept-study has been initiated by Pharma Holdings AS to demonstrate if the percutaneous application of LTX-109 in a gel vehicle is a safe treatment of Hidradenitis suppurativa and to identify clinical response to intervention, as well as to identify if covariates such as age, disease duration, smoking state and BMI influence patient-reported measures investigate.

Request Sample to know more about the therapies expected to capture the maximum patient pool @ Hidradenitis Suppurativa Emerging Therapies and Forecast 

The Hidradenitis Suppurativa Pipeline reports offer a holistic scenario of the ongoing clinical trials, partnerships taking place in the domain, latest happenings in the HS domain, and growth prospects across the Hidradenitis Suppurativa space.

Hidradenitis Suppurativa Overview

Hidradenitis Suppurativa is a recurring disease characterized by swollen, painful lesions that affect the armpit (axillae), groin, anal, and breast regions.

The disease is progressive in nature and leads to single boil-like, pus-filled abscesses into hard lumps, then deep-seated, painful, frequently inflamed clusters of recurrent infiltration lesions. 

It can be an extremely painful and debilitating condition, however, is rarely life-threatening affecting individuals with compromised immune systems.  

Learn more about the disease, treatments, and pipeline therapies @ Hidradenitis Suppurativa Pipeline Assessment 

Hidradenitis Suppurativa Pipeline Drugs 

DrugCompanyPhaseMoARoA
Bimekizumab (MABp1)UCB BiopharmaIIIIL17A protein inhibitors; IL17F protein inhibitorsSubcutaneous
SecukinumabNovartisIIIIL17A protein inhibitorsSubcutaneous
IFX-1InflaRxIIComplement C5a inhibitorsIntravenous
INCB054707 Incyte CorporationIIJanus kinase 1 inhibitorsOral
AvacopanChemoCentryxIIComplement C5a receptor antagonistsOral
BermekimabJanssen Research and DevelopmentIIInterleukin 1 alpha inhibitorsSubcutaneous
ImsidolimabAnaptysBioIIInterleukin 36 receptor antagonistsNA
CSL324CSL BehringIGranulocyte colony stimulating factor inhibitorsIntravenous
AMP-001IntegoGen, LLCINANA
KT-474Kymera TherapeuticsIInterleukin-1 receptor-associated kinase degradersOral
SonelokimabMoonLake ImmunotherapeuticsIIL17A protein inhibitors; IL17F protein inhibitorsParenteral
BrilacidinInnovation PharmaceuticalsPreclinicalImmunomodulatorsNA

Request for Sample to know more @ Hidradenitis Suppurativa Pipeline Analysis, Key Companies, and Futuristic Trends 

Hidradenitis Suppurativa Therapeutics Assessment 

The Hidradenitis Suppurativa Pipeline report puts forward a complete view of the Hidradenitis Suppurativa emerging novel pipeline therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.

By Product Type

  • Mono
  • Mono/Combination

By Stage

  • Discovery 
  • Pre-clinical
  • IND
  • Phase I
  • Phase II
  • Phase III
  • Pre-registration

By Molecule Type 

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

By Route of Administration

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

By Mechanism of Action

  • Biologics
  • Granulocyte-colony stimulating factor inhibitors
  • IL17A protein inhibitors
  • MAP-kinase-activated kinase 2 inhibitors
  • Complement C5a inhibitors
  • Interleukin 1 alpha inhibitors
  • Janus Kinase 1 inhibitors

By Targets 

  •  Protein
  • Monoclonal antibody

For rich insights into pipeline therapies and assessment, visit Hidradenitis Suppurativa Pipeline Emerging Novel Therapies 

Scope of the Hidradenitis Suppurativa Pipeline Report

Coverage: Global

Key Players: Janssen, InflaRx, Incyte Corporation, Novartis, CSL Behring, ChemoCentryx, UCB Biopharma S.P.R.L., Eli Lilly and Company, AbbVie, ChemoCentryx, IntegoGen, Pfizer, TO Pharmaceuticals, Kymera Therapeutics, Aclaris Therapeutics, Amgen, Innovation Pharmaceuticals, AnaptysBio, MoonLake Immunotherapeutics, IntegoGen, LLC and several others.

Key Hidradenitis Suppurativa Pipeline Therapies: Bimekizumab (MABp1), IFX-1, INCB054707, Secukinumab, Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody, Avacopan, Bimekizumab, and others.

Dive Deeper into Hidradenitis Suppurativa Emerging Therapies, Treatments, and Ongoing Clinical Trials 

Table of Contents 

1Report Introduction
2Executive Summary
3Hidradenitis Suppurativa Disease Overview
4Hidradenitis Suppurativa Pipeline Therapeutics Comparative Analysis
5Hidradenitis Suppurativa Therapeutics Assessment
6Hidradenitis Suppurativa – DelveInsight's Analytical Perspective
7In-depth Commercial Hidradenitis Suppurativa Assessment
8Hidradenitis Suppurativa Collaboration Deals 
9Late Stage Hidradenitis Suppurativa Products (Phase III)
10Mid-Stage Hidradenitis Suppurativa Products (Phase II)
11Early Stage Hidradenitis Suppurativa Products (Phase I)
12Pre-clinical and Discovery Stage Hidradenitis Suppurativa Products
13Inactive Hidradenitis Suppurativa Pipeline Products 
14Key Hidradenitis Suppurativa Products
15Unmet Needs
16Hidradenitis Suppurativa Market Drivers and Barriers
17Future Perspectives and Conclusion
18Analyst Views
19Key Hidradenitis Suppurativa Companies
20Appendix

Learn more about the report offerings @ Hidradenitis Suppurativa Drg Pipeline Therapies, Novel Drug Delivery Platforms and Emerging Trends

Related Reports

Atopic Dermatitis Market 

DelveInsight's "Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast-2030" report. 

Acne Vulgaris Market

DelveInsight's "Acne Vulgaris Market Insights, Epidemiology, and Market Forecast-2030" report.

Acral lentiginous melanoma Market 

DelveInsight's "Acral lentiginous melanoma - Market Insights, Epidemiology, and Market Forecast-2030" report.

Actinic Keratosis Market

DelveInsight's "Actinic Keratosis Market Insights, Epidemiology, and Market Forecast-2030" report.

Alopecia Areata Market

DelveInsight's "Alopecia Areata - Market Insights, Epidemiology, and Market Forecast-2030" report.

Androgenetic Alopecia Market

DelveInsight's "Androgenetic Alopecia Market Insights, Epidemiology, and Market Forecast-2030" report. 

Cholestatic Pruritus Market

DelveInsight's "Cholestatic Pruritus Market Insights, Epidemiology, and Market Forecast-2030" report. 

Browse through our posts 

Insights into Rosacea Pipeline

Rosacea Pipeline therapies include FMX103 (Foamix Pharmaceuticals), Epsolay (Sol-Gel Technologies), ACU-D1 (Accuitis), HY01 (Hovione Scientia Limited), AFX4031 (Afecta Pharmaceuticals), AOB103 (AOBiome), and several others.

ABSSSI Market and Antibiotic Resistance 

The ABSSSI pipeline appears quite active with several emerging candidates in Phase III and Phase II stages of development, with many more in the early stages of development, estimates DelveInsight.

Epidermolysis Bullosa Market Size

Novel therapies such as FCX-007 (Fibrocell Technologies), CCP-020 (Castle Creek Pharmaceuticals), RGN-137 (RegeneRx/Lenus Therapeutics), AP-101 (Amryt Pharma), EB-101 (Abeona Therapeutics), KB103 (Krystal Biotech), and S-005151 (Redasemtide (Shionogi)) and others aim to provide effective treatment for Epidermolysis bullosa.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News 

 

Contact Data